In This Article:
-
Revenue (Q4 2024): $1.95 million, a 10.6% increase year-over-year.
-
Full Year Revenue (2024): $7 million, a 13% increase from 2023.
-
Gross Profit (Q4 2024): $469,000, a decrease of 7.1% from Q4 2023.
-
Gross Margin (Q4 2024): 24.1%, down from 28.7% in Q4 2023.
-
Operating Expenses (Q4 2024): $9.8 million, a 55.8% increase from Q4 2023.
-
Net Loss (Q4 2024): $9.1 million or $0.19 per share, compared to $5.4 million or $0.16 per share in Q4 2023.
-
Gross Margin (Full Year 2024): 21.5%, down from 29.1% in 2023.
-
Operating Expenses (Full Year 2024): $35 million, a 52.5% increase from 2023.
-
Net Loss (Full Year 2024): $32 million or $0.76 per share, compared to $19.9 million or $0.82 per share in 2023.
-
Cash and Cash Equivalents (End of 2024): $34.7 million, down from $39 million at the end of 2023.
Release Date: March 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
CGuard revenue reached a new quarterly high of $1.95 million in Q4 2024, reflecting a 10.6% growth year-over-year.
-
InspireMD Inc (NASDAQ:NSPR) is on track for anticipated US approval and launch of CGuard Prime in the first half of 2025.
-
The C-GUARDIANS pivotal clinical trial showed unprecedented low major adverse event rates, supporting the efficacy of CGuard Prime.
-
InspireMD Inc (NASDAQ:NSPR) has strategically positioned its new headquarters in Miami, Florida, to support the anticipated US launch.
-
The company has onboarded over a dozen world-class field sales professionals, preparing for a robust US market entry.
Negative Points
-
Gross profit for Q4 2024 decreased by 7.1% to $469,000 due to increased costs of goods sold.
-
Gross margin decreased to 24.1% in Q4 2024 from 28.7% in Q4 2023, primarily due to higher material and labor costs.
-
Total operating expenses for Q4 2024 increased by 55.8% to $9.8 million, driven by higher salaries and share-based compensation.
-
Net loss for Q4 2024 totaled $9.1 million, an increase from a net loss of $5.4 million in the same period in 2023.
-
Cash and cash equivalents decreased to $34.7 million as of December 31, 2024, from $39 million the previous year.
Q & A Highlights
Q: Can you provide more details on the US approval timing for CGuard Prime and any potential impacts from changes at the FDA? A: Marvin Slosman, CEO, stated that they remain optimistic about receiving approval in the first half of 2025. They have been engaging in a productive, interactive review process with the FDA, and there are no significant impacts from the broader changes at the FDA affecting their timeline.